Literature DB >> 33930900

De-escalation of Prasugrel Results in Higher Percentage of Patients within Optimal Range of Platelet Reactivity: Analysis from the HOST-REDUCE-POLYTECH-ACS Trial.

Hak Seung Lee1, Kyung Woo Park1, Jeehoon Kang1, Jung-Kyu Han1, Hyo-Soo Kim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33930900     DOI： 10.1055/a-1496-7987

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   6.681


× No keyword cloud information.
  2 in total

1.  Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Kai Song; Xuan Jin; Moo-Hyun Kim; Jia-Xin Li; Cai-De Jin; Song-Lin Yuan; Zhao-Yan Song; En-Ze Jin; Kwang-Min Lee; Kyung-Hee Lim; Young-Rak Cho
Journal:  J Clin Med       Date:  2022-04-28       Impact factor: 4.964

2.  Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI.

Authors:  You-Jeong Ki; Bong Ki Lee; Kyung Woo Park; Jang-Whan Bae; Doyeon Hwang; Jeehoon Kang; Jung-Kyu Han; Han-Mo Yang; Hyun-Jae Kang; Bon-Kwon Koo; Dong-Bin Kim; In-Ho Chae; Keon-Woong Moon; Hyun Woong Park; Ki-Bum Won; Dong Woon Jeon; Kyoo-Rok Han; Si Wan Choi; Jae Kean Ryu; Myung Ho Jeong; Kwang Soo Cha; Hyo-Soo Kim
Journal:  Korean Circ J       Date:  2021-12-21       Impact factor: 3.243
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.